UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
BRUSSELS , April 2, 2020 /PRNewswire/ -- UCB today announced that the acquisition of…
Börse:
79,960€
1,50%
Echtzeit-Aktienkurs UCB S.A.
Bid:
79,560€
Ask:
80,360€
Nachrichtenticker der UCB S.A. Aktie
UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
BRUSSELS , April 2, 2020 /PRNewswire/ -- UCB today announced that the acquisition of Ra Pharmaceuticals, Inc. has been successfully completed and Ra Pharma is now a wholly-owned subsidiary of UCB.......
Den vollständigen Artikel können Sie lesen unter: https://www.barchart.com/story/news/pr-newswire/4643202/ucb-completes-the-acquisition-of-ra-pharmaceuticals-to-deliver-differentiated-therapies-to-patients.
Den vollständigen Artikel können Sie lesen unter: https://www.barchart.com/story/news/pr-newswire/4643202/ucb-completes-the-acquisition-of-ra-pharmaceuticals-to-deliver-differentiated-therapies-to-patients.